CA-UNIPHORE
14.8.2024 15:01:34 CEST | Business Wire | Press release
Uniphore, one of the world’s largest AI-native, enterprise-class companies, today announced the appointment of Ravi Mayuram as the company’s new Chief Technology Officer (CTO). Mayuram brings over 25 years of experience in engineering leadership and is poised to further Uniphore's leadership in Enterprise AI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240814179209/en/
Ravi Mayuram, CTO of Uniphore. (Photo: Business Wire)
At Uniphore, Mayuram will lead the engineering team and take on the scaling up of Uniphore’s engineering platform, technology and AI groups, while ensuring the highest standards of security and performance.
Mayuram comes to Uniphore with a deep leadership background, having held several senior technical and management positions at leading software companies including Couchbase, BEA, HP, Informix, Oracle, and Siebel Systems. As an engineering leader, he has built teams from the ground up – in both established companies and startups – where he has been responsible for building systems, including operating systems, distributed databases, PaaS, SaaS as well as Edge and IoT systems.
Most recently, Mayuram was the Chief Development Officer at Luminary Cloud, where he led Products, Design and Engineering. Before that he was CTO of Couchbase, a leading cloud-native NoSQL database company, where he oversaw innovation, development and delivery of their popular database platform, and was instrumental in making them a successful public company. He has also led innovations in the areas of social graph, search and analytics at Oracle, and helped to initiate the company’s Cloud Collaboration Platform. His startup experience includes BroadBand Office (a Kleiner-Perkins venture), and Plumtree (acquired by BEA).
“It is with tremendous excitement that we welcome Ravi Mayuram to the Uniphore leadership team,” said Umesh Sachdev, CEO and co-founder of Uniphore. “As Uniphore becomes the preferred AI partner for the world’s largest enterprises, I am confident Ravi will help turbocharge our AI leadership and innovation into the future.”
Mayuram expressed enthusiasm about joining Uniphore, stating, “I am honored to join Uniphore at such a pivotal time in the company’s journey. Uniphore’s culture of AI innovation is unlike any other in the industry with technology that is tried, tested and trusted by the biggest companies. I am eager to work with this talented team of world-class engineers and leaders to further advance Uniphore’s technology and deliver even greater value to customers.”
For additional information on the U and Q product lines, please click here. To stay up to date with the latest commentary, follow Uniphore’s blog, or connect on LinkedIn, X, Facebook, or Instagram.
About Uniphore
Uniphore is one of the largest B2B AI-native companies – decades-proven, built-for-scale, and designed for the Enterprise. The company drives business outcomes, across multiple industry verticals, and the largest global deployments. Uniphore infuses AI into every part of the Enterprise that impacts the customer. We deliver the only multimodal AI architecture centered on customers that combines Generative AI, Knowledge AI and Emotion AI and Workflow Automation and a co-pilot to guide you. We understand better than anyone how to capture voice, video, text, and how to analyze all types of data. As AI becomes more powerful, every part of the Enterprise that impacts the customer will be disrupted. We believe the future will run on the connective tissue between people, machines and data: all in service of creating the most human processes and experiences for customers and employees.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240814179209/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom